Please select the option that best describes you:
Has the role of radium-223 changed in the treatment of prostate cancer given the availability of newer anti-androgen medications to treat metastatic prostate cancer?
Answer from: Medical Oncologist at Academic Institution
Radium-223 remains a valuable palliative therapy for men with symptomatic bone metastatic prostate cancer. As we utilize abi/enza/daro/apa with ADT earlier in the mHSPC or M0 CRPC settings, the number of available and effective treatments in the mCRPC diminish. I do not recommend radium-...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
I think that this is a moving target as the landscape of prostate cancer is constantly changing. I think that the argument could be made either to support or disagree with the premise of the question. On the one hand, the earlier use of novel anti androgens will mean that men with mCRPC will have be...